Financials in USD. Standardized financial statements.
A compact view of how Sigilon Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue? | $12.94M | $9.60M | $13.37M | $14.15M | $4.64M |
| Revenue Growth? | +34.8% | -28.2% | -5.5% | +205.3% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $12.94M | $9.60M | $13.37M | $14.15M | $4.64M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $56.61M | $85.23M | $66.02M | $58.28M | $27.71M |
| Operating Income? | -$43.67M | -$75.64M | -$52.64M | -$44.12M | -$23.07M |
| EBITDA? | -$38.88M | -$75.01M | -$53.18M | -$42.40M | -$22.08M |
| Income Before Tax | -$43.56M | -$77.31M | -$54.61M | -$43.92M | -$22.77M |
| Income Tax Expense | -$105,000 | $925,000 | $259,000 | $644,000 | $0 |
| Net Income? | -$43.46M | -$78.24M | -$54.87M | -$44.57M | -$22.77M |
| EPS? | $-1.34 | $-31.92 | $-22.67 | $-27.53 | $-18.85 |
| Diluted EPS? | $-1.34 | $-31.92 | $-22.67 | $-27.53 | $-18.85 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality